Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5401-5415

  Iyer, Swathi V ^a   Parrales, Alejandro ^a   Begani, Priya ^a   Narkar, Akshay ^a   Adhikari, Amit S ^b   Martinez, Luis A ^c   Iwakuma, Tomoo ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Allele specific siRNA silencing; Dominant negative; Gain of function; Mutant p53; Oncogene addiction

Indexed keywords

DOXORUBICIN; NUTLIN 3; PROTEIN P53; SMALL INTERFERING RNA; IMIDAZOLE DERIVATIVE; MESSENGER RNA; MUTANT PROTEIN; PIPERAZINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GAIN OF FUNCTION MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR SUPPRESSOR GENE; ALLELE; ANIMAL; CARCINOGENESIS; CELL ADHESION; CELL MOTION; DOMINANT GENE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ALLELES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENESIS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; GENES, DOMINANT; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; MICE; MUTANT PROTEINS; MUTATION; NEOPLASMS; PIPERAZINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84958068650     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6634     Document Type: Article

References (56)

1. McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol. 2011; 103:464-467.
2. Yan R, Hallam A, Stockley PG and Boyes J. Oncogene dependency and the potential of targeted RNAi-based anticancer therapy. Biochem J. 2014; 461:1-13.
3. Cheok CF, Verma CS, Baselga J and Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011; 8:25-37.
4. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
5. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J and Epstein CB. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci. 1995; 768:111-128.
6. Adhikari AS and Iwakuma T. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi. 2009; 100:217-228.
7. Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell. 2014; 157:382-394.
8. Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ and Xie LP. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol. 2013; 11:22.
9. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS and Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008; 22:1337-1344.
10. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006; 25:304-309.
11. Lim LY, Vidnovic N, Ellisen LW and Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 2009; 101:1606-1612.
12. Yan W, Liu G, Scoumanne A and Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res. 2008; 68:6789-6796.
13. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M and Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res. 2007; 35:2093-2104.
14. Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY and Kwok TT. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther. 2007; 6:1054-1061.
15. Matsushima S, Ohtsuka K, Ohnishi H, Fujiwara M, Nakamura H, Morii T, Kishino T, Goto H and Watanabe T. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2014; 9:1377-1384.
16. Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake D, Leachman SA, Milstone LM, McLean WH and Kaspar RL. Single-nucleotide-specific siRNA targeting in a dominantnegative skin model. J Invest Dermatol. 2008; 128:594-605.
17. Courtney DG, Atkinson SD, Moore JE, Maurizi E, Serafini C, Pellegrini G, Black GC, Manson FD, Yam GH, Macewen CJ, Allen EH, McLean WH and Moore CB. Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type I. Invest Ophthalmol Vis Sci. 2014; 55:977-985.
18. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL and Paulson HL. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A. 2003; 100:7195-7200.
19. Brummelkamp TR, Bernards R and Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002; 2:243-247.
20. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G and Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002; 99:14849-14854.
21. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK and Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119:861-872.
22. Hindupur SK, Balaji SA, Saxena M, Pandey S, Sravan GS, Heda N, Kumar MV, Mukherjee G, Dey D and Rangarajan A. Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells. Breast Cancer Res. 2014; 16:420.
23. Perez-Garcia A, Carrion-Navarro J, Bosch-Fortea M, Lazaro-Ibanez E, Prat-Acin R and Ayuso-Sacido A. Genomic instability of surgical sample and cancerinitiating cell lines from human glioblastoma. Front Biosci (Landmark Ed). 2012; 17:1469-1479.
24. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, Evans DG and Birch JM. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene. 1997; 14:865-871.
25. Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA and Donehower LA. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014; 232:522-533.
26. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D and Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998; 17:4657-4667.
27. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S and Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990; 50:7717-7722.
28. Brosh R and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9:701-713.
29. Davidoff AM, Kerns BJ, Iglehart JD and Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991; 51:2605-2610.
30. Davidoff AM, Kerns BJ, Pence JC, Marks JR and Iglehart JD. p53 alterations in all stages of breast cancer. J Surg Oncol. 1991; 48:260-267.
31. Hong B, van den Heuvel AP, Prabhu VV, Zhang S and El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Current drug targets. 2014; 15:80-89.
32. Lim SO, Kim H and Jung G. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS letters. 2010; 584:2231-2236.
33. Luo J, Solimini NL and Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136:823-837.
34. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith LM, Jain M and Batra SK. Activated KrasG(1)(2)D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer. 2011; 104:1038-1048.
35. Yang G, Thompson JA, Fang B and Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene. 2003; 22:5694-5701.
36. Zhen Y, Guanghui L and Xiefu Z. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther. 2014; 21:491-497.
37. Faltus T, Yuan J, Zimmer B, Kramer A, Loibl S, Kaufmann M and Strebhardt K. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia. 2004; 6:786-795.
38. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B and Kiessling R. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer. 2004; 108:71-77.
39. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D and Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119:847-860.
40. Weisz L, Oren M and Rotter V. Transcription regulation by mutant p53. Oncogene. 2007; 26:2202-2211.
41. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK and Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012; 21:793-806.
42. Chan WM, Siu WY, Lau A and Poon RY. How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol. 2004; 24:3536-3551.
43. Yu X, Narayanan S, Vazquez A and Carpizo DR. Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis. 2014; 19:1055-1068.
44. Bykov VJ and Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS letters. 2014; 588:2622-2627.
45. Cinatl J, Speidel D, Hardcastle I and Michaelis M. Resistance acquisition to MDM2 inhibitors. Biochem Soc Trans. 2014; 42:752-757.
46. Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem. 2014; 57:7859-7873.
47. Bora RS, Gupta D, Mukkur TK and Saini KS. RNA interference therapeutics for cancer: challenges and opportunities (review). Mol Med Rep. 2012; 6:9-15.
48. Rungta RL, Choi HB, Lin PJ, Ko RW, Ashby D, Nair J, Manoharan M, Cullis PR and Macvicar BA. Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Molecular therapy. Nucleic acids. 2013; 2:e136.
49. Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012; 4:147ra112.
50. Ran R, Liu Y, Gao H, Kuang Q, Zhang Q, Tang J, Huang K, Chen X, Zhang Z and He Q. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: A potential candidate for overcoming multi-drug resistance. International journal of pharmaceutics. 2014; 477:590-600.
51. Hyodo M, Sakurai Y, Akita H and Harashima H. "Programmed packaging" for gene delivery. J Control Release. 2014; 193:316-323.
52. Shangary S and Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008; 14:5318-5324.
53. Zajkowicz A, Krzesniak M, Matuszczyk I, Glowala-Kosinska M, Butkiewicz D and Rusin M. Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol. Molecular biology reports. 2013; 40:5013-5026.
54. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR and Iwakuma T. CD117 and Stro-1 Identify Osteosarcoma Tumor-Initiating Cells Associated with Metastasis and Drug Resistance. Cancer Res. 2010; 70:4602-4612.
55. Chen Y, Lu B, Yang Q, Fearns C, Yates JR, 3rd and Lee JD. Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res. 2009; 69:3713-3720.
56. Carstens MJ, Krempler A, Triplett AA, Van Lohuizen M and Wagner KU. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem. 2004; 279:35984-35994.